XML 51 R37.htm IDEA: XBRL DOCUMENT
v3.25.1

SEGMENT INFORMATION (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
Segment Reporting [Abstract] |
SCHEDULE OF SIGNIFICANT EXPENSE CATEGORIES | The table below summarizes the significant expense categories regularly reviewed by the CODM for the years ended December 31, 2024, and 2023: SCHEDULE OF SIGNIFICANT EXPENSE CATEGORIES
|  | 2024 |  |  | 2023 |
|  | For the year ended December 31, |
|  | 2024 |  |  | 2023 |
License and other revenues |  | $ | — |  |  | $ | 3,500 |
Research and development costs |  |  |  |  |  |  |  |
Salaries & related costs |  |  | 15,345 |  |  |  | 11,373 |
Non-cash stock-based compensation |  |  | 1,561 |  |  |  | 1,086 |
Other research and development costs (a) |  |  | 17,454 |  |  |  | 18,632 |
Total research and development costs |  |  | 34,360 |  |  |  | 31,091 |
General and administrative costs |  |  |  |  |  |  |  |
Salaries & related costs |  | $ | 10,729 |  |  | $ | 6,942 |
Non-cash stock-based compensation |  |  | 5,067 |  |  |  | 3,682 |
Pre-commercial preparation costs |  |  | 4,818 |  |  |  | 1,224 |
Other general and administrative costs (b) |  |  | 9,237 |  |  |  | 7,156 |
Total general and administrative costs |  | $ | 29,851 |  |  | $ | 19,004 |
Other segment items (c) |  |  | (477 | ) |  |  | 7,593 |
Net loss |  | $ | (63,734 | ) |  | $ | (54,188 | )
(a) | Other research and development expenses include, but are not limited to lab supplies, preclinical and development costs, clinical trial costs, manufacturing and manufacturing facility costs, costs associated with regulatory approvals, depreciation on lab supplies and manufacturing facilities, and consultant-related expenses.
(b) | Other general and administrative expenses primarily consist of office facility costs, public reporting company related costs, professional fees (e.g., legal expenses) and other general operating expenses not otherwise included in research and development expenses.
(c) | Other segment items includes royalties, interest income, interest expense, change in fair value of warrant and derivative liabilities and other income.

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration